Health Trials

Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma

ConditionCholangitis
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorHepatopancreatobiliary Surgery Institute of Gansu Province

About this trial

The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar cholangiocarcinoma.

Eligibility criteria

Qualifiers

Type Ⅰ、Ⅱ、Ⅲ、Ⅳ of Hilar Cholangiocarcinoma;

Age: 18~90 years old;

Underwent diagnostic and therapeutic ERCP;

Disqualifiers

Coagulation dysfunction(INR>1.3) or/and low peripheral blood platelet count （PLT <50x10^9/L）;

Preoperative acute cholangitis;

Preoperative acute pancreatitis;

Preoperative hemobilia or hemorrhage of digestive tract;

Trial design

Treatments tested in this trial

  • Injection of 37℃ contrast agent

Treatment groups

100 Participants
are divided into 2 treatment groups

Locations

3
The first hospital of Lanzhou university730000, LanzhouGansu, China
The first affiliated hospital of Xi 'an jiaotong university710061, Xi'anShaanxi, China
Tianjin Nankai Hospital300100, TianjinTianjin Municipality, China

Sponsors and collaborators

Hepatopancreatobiliary Surgery Institute of Gansu Province

Lead sponsor

Source ClinicalTrials.gov